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Cryoglobulinaemia may cause cutaneous vasculitis and
glomerulonephritis, potentially leading to end stage renal
failure. An important proportion of cryoglobulinaemias are
secondary to hepatitis C virus infection. Emerging antiviral
treatment options offer a chance for causal therapy of these
cases of cryoglobulinaemia. This review summarises the
classification and clinical and therapeutic aspects of
cryoglobulinaemic vasculitis and glomerulonephritis.
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T
he manifestations of small vessel vasculitides
are often protean and may involve both the
skin and internal organs, including the kidney.
To avoid potentially life-threatening complications,
correct differential diagnosis and exclusion of
internal organ involvement are particularly impor-
tant. Previously, cryoglobulinaemic vasculitides
were assumed to be primary or essential. It has
now become evident that the majority of cryoglo-
bulinaemic vasculitides are secondary manifesta-
tions of other diseases, especially of viral origin,
such as chronic hepatitis C virus (HCV). This
recognition offers an opportunity for causal rather
than symptomatic therapy of these vasculitides.
The different causes, types and complications of
cryoglobulinaemic vasculitis, including glomerulo-
nephritis, are reviewed here.
DEFINITIONS AND CLASSIFICATIONS
Cryoglobulins are cold-precipitable immunoglobu-
lins from serum. Cryoglobulinaemia remains
asymptomatic in most cases but can lead to
immune complex tissue deposition, causing cryo-
globulinaemic vasculitis. Based on the classifica-
tion introduced in 1974,1 three main and one
additional2 categories of cryoglobulins are cur-
rently recognised (table 1).
Cryoglobulinaemic vasculitis belongs to the large
group of cutaneous vasculitides that originate from
inflammation in the small or medium sized
vasculature (the so-called small vessel vasculi-
tides), leading to clinically apparent skin lesions,
and in some cases also to internal organ involve-
ment.6 Vasculitis can be classified using clinical
(tissues and vasculature presumed to be involved
on clinical grounds), histopathological (tissues and
vessels involved, type of vascular destruction) or
immunopathological (identified molecular patho-
genesis) terms, or their combination.6–8 The most
widely used classification today is that coined by
the Chapel Hill consensus conference which is
mainly based on anatomical distinctions of the
dominant vessels affected (table 2).8
For the clinician, establishing the hypothesis
that a patient may have small vessel cutaneous
vasculitis is the first step. From a pathogenetic
point of view, the largest group of small vessel
dermal vasculitides consists of the immune com-
plex mediated types.6–8 These include mainly
cryoglobulinaemic vasculitis, Henoch–Scho¨nlein
purpura, urticaria vasculitis and vasculitis asso-
ciated with malignancy (see table 2 for details).
Vasculitis affecting not only the small but also
medium sized vessels includes the so-called pauci-
immune forms (table 3).8 Other disorders causing
cutaneous vasculitis include the following: inflam-
matory bowel disease, Behc¸et’s disease and septic
emboli, as in bacterial endocarditis, and EED
(erythema elevatum diutinum), an immune com-
plex vasculitis of unknown aetiology.6 It may be
associated with HIV infection and usually presents
with symmetrically distributed purple plaques and
nodules on the extensor surfaces.13 14
PATHOGENESIS/AETIOLOGY
Type II and III (mixed) cryoglobulinaemia is
strongly associated with HCV infection, and since
the first reports15 the causative role of HCV is now
widely acknowledged.4 16 The presence of cryoglo-
bulins increases with duration of HCV infection;
30–50% of HCV positive patients have mixed
cryoglobulins while in selected patients with
chronic HCV infection, cryoglobulins are found in
55–90% of cases.17–19 Rheumatoid factor is positive
in most patients with chronic HCV infection.18
Type II cryoglobulinaemia is more strongly asso-
ciated with HCV than type III cryoglobulinaemia
(that is, 90% and 70%, respectively).12 An associa-
tion of cryoglobulinaemia with chronic hepatitis B
virus (HBV) infection has been suggested but is
highly questionable as the prevalence of cryoglo-
bulins in HBV infected patients is similar to that in
other chronic liver diseases.17 At best, approxi-
mately 2% of mixed cryoglobulinaemic vasculitides
seem to be attributable to HBV infection, according
to one study.20
Type III cryoglobulins have been reported to
occur as a transient phenomenon in many
different infections.4 It is thought that partially
uncontrolled B cell clone proliferation, which can
often be detected in patients with long standing
HCV infection, underlies the formation of mixed
Abbreviations: ANCA, antineutrophil cytoplasmic
antibody; HBV, hepatitis B virus; HCV, hepatitis C virus;
MPGN, membranoproliferative glomerulonephritis
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Table 1 Types of cryoglobulinaemia, composition of cryoprecipitates and associated
diseases1 2
Type of cryoglobulinaemia
(estimated frequency3) Composition of cryoprecipitates Associated or underlying diseases
Type I (25%) Monoclonal IgM (sometimes IgG, IgA) Lymphoproliferative diseases, plasma cell
dyscrasias, multiple myeloma,
Waldenstro¨m’s macroglobulinaemia,
MGUS
Type II* (25%) Combination of monoclonal (usually
IgM) and polyclonal (usually IgG)
HCV infection
Type III* (50%) Polyclonal Igs HCV infection, connective tissue diseases
Type II–III
(frequency unknown)
Oligoclonal IgM HCV infection, other infections,
autoimmune diseases, lymphoproliferative
diseases, chronic liver disease,
proliferative glomerulonephritis
HCV, hepatitis C virus; MGUS, monoclonal gammopathy of undetermined significance.
*Type II and III cryoglobulinaemias are classically referred to as ‘‘mixed cryoglobulinaemias’’ because of their polyclonal
component. Type II–III is an intermediate state between the entirely polyclonal type III and the monoclonal, polyclonal type
II. Some authors presume a continuous transition from a purely polyclonal composition to a partially monoclonal
component by a process of successive clonal selection.2 4 5 The monoclonal IgM components usually have rheumatoid
factor activity—that is, they bind to the Fc portion of IgG leading to immune complex formation.
Table 2 Types of vasculitis according to the dominant vessels affected, as defined by the
Chapel Hill consensus conference8
Dominant vessels affected Type of vasculitis (pathomechanism) Specific diagnostic hallmarks
Small vessels Cutaneous leucocytoclastic angiitis
(unknown aetiology, drug induced/allergic)
Eventual drug history (possible serum IgE
elevation), absence of cryoglobulins or IgA
on histology, negative immune serology
Henoch-Scho¨nlein purpura
(IgA deposition)
Increased serum IgA, usually normal serum
complement, tissue IgA deposition,
especially in paediatric patients, triggered
by infections,9–11 clinical triad or tetrad of
purpura, arthralgia, gastrointestinal
symptoms and renal failure2 12
Mixed cryoglobulinaemia (cryoglobulin
deposition)
Serum cryoglobulins, often low serum C4,
tissue deposition of cryoglobulin and
complement
Small to medium vessels Wegner’s granulomatosis (mostly ANCA
associated)
ANCA, renal and nasopharyngeal
involvement
Churg–Strauss syndrome (mostly ANCA
associated, eosinophilia)
ANCA, eosinophilia
Microscopic polyangiitis (mostly ANCA
associated)
ANCA
Medium vessels Polyarteritis nodosa Clinically medium vessel affection with
negative immune serology
Kawasaki syndrome (unknown) ESR acceleration, C-reactive protein
increased
Large vessels Temporal arteritis (unknown) ESR acceleration, C-reactive protein
increased
Takayasu arteritis (unknown) ESR acceleration
ANCA, antineutrophil cytoplasmic antibody; ESR, erythrocyte sedimentation rate.
Table 3 Pauci-immune forms of vasculitis8
Wegener’s granulomatosis
Churg–Strauss syndrome
Drug induced ANCA associated vasculitis
Microscopic polyangiitis and polyarteriitis nodosa
Connective tissue disease associated vasculitis
Systemic lupus erythematosus
Rheumatoid arthritis
Sjo¨gren’s syndrome
ANCA, antineutrophil cytoplasmic antibody.
Table 4 Frequent associations of mixed cryoglobulins4 22
Infections
HIV, bacterial endocarditis
Collagen vascular diseases
Sjo¨gren’s syndrome
Systemic lupus erythematosus
Rheumatoid arthritis
Dermatomyositis/polymyositis
B cell non-Hodgkin’s lymphoma
Chronic lymphocytic leukaemia
The aetiologies of cryoglobulinaemia were found to be 75% infectious, 24%
autoimmune and 6% neoplastic in one study.23
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cryoglobulins.16 21 Indeed, HCV is also a lymphotropic virus and
it is worth noting that 6–28% of patients with type II
cryoglobulinaemia develop symptomatic lymphoma after 4–
10 years of follow-up.6 21
Importantly, non-viral liver disease (for example, due to
alcohol abuse or immunological autoimmune hepatitis) has
also been associated with increased rates of mixed cryoglobulin
formation.17 Other associations of mixed cryoglobulins are
summarised in table 4.
MANIFESTATIONS OF CRYOGLOBULINAEMIC
VASCULITIS AND CLINICAL APPROACH
Between 2% and 15% of cryoglobulin positive patients are
considered to develop cryoglobulinaemic vasculitis.6 24 Frequent
symptoms and serological findings are listed in table 5. An
important first diagnostic step is detection of serum cryoglo-
bulins. For correct detection, blood samples must be constantly
kept at 37 C˚ on the way to the laboratory. Cold precipitation can
be Ca++ dependent and may take up to a week, as described
previously.2 25 Encountered cryoglobulin levels range from as
low as 0.05 g/l to 10 g/l and sometimes higher, depending on
the type of cryoglobulin and the laboratory.1 2 26 Standard
detection uses immunoelectrophoresis and immunofixation;
the more sensitive methods for detection of oligoclonal
components of type III cryoglobulins are immunoblotting and
two dimensional electrophoresis.4 Cryoprecipitates may deplete
HCV antibody and HCV antigens from serum, leading to a false
negative hepatitis serology. This can be overcome by paired
testing from both the serum and cryoprecipitate.4
DERMATOLOGICAL SYMPTOMS AND SIGNS
The clinical hallmark of cutaneous vasculitis is palpable
purpura that usually occurs in the lower extremities. Possible
manifestations of purpura are: (i) multiple small papules
covering larger skin areas (fig 1A, from a patient with
cutaneous small vessel vasculitis); (ii) larger confluent necro-
tising lesions (fig 1B, from a patient with polyarteriitis nodosa);
and (iii) livedo racemosa, marble-like changes to the skin that
Table 5 Clinical and serological findings in patients with
cryoglobulinaemic vasculitis4
Frequency (%)
Clinical
Purpura 50–100
Arthralgias, weakness .70
Combination of purpura/arthralgia/weakness* ,40
Polyneuropathy 40–70
Raynaud’s phenomenon 20
Secondary Sjo¨gren’s syndrome
CNS involvement
Gastrointestinal involvement
Renal involvement
Serological
Anti-HCV-antibodies 90
Detectable HCV RNA 85
Hypocomplementaemia (ie, C4) 90
Elevated rheumatoid factor 70–100
Antinuclear antibodies (ANAs) 20
Antismooth muscle antibodies 20–25
Antiphospholipid antibodies 5–20
ANCAs ,5
ANCA, antineutrophil cytoplasmic antibody; HCV, hepatitis C virus.
*So-called cryoglobulinaemic vasculitis syndrome.
SS-A-/SS-B antibody negative.
A B
C D
Figure 1 Skin lesions relevant for the
differential diagnosis of cutaneous vasculitis.
(A) Papular lesions in a vasculitis marked by
leucocytoclastic vasculitis on histology. (B)
Polyarteriitis nodosa with papular necrosis
and livedo racemosa-like colouring of the
skin. (C) Epidermal oedema seen in urticaria.
(D) Prurigo simplex. Itching papular lesions.
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are mostly present in necrotising vasculitides (fig 1B). These
patterns may occur singularly, serially or in conjunction, and
they are not specific to the type of vasculitis, thus precluding a
diagnosis on clinical grounds alone. Furthermore, vasculitis of
the skin must be differentiated from an array of non-vasculitic
lesions mimicking its aspect that include plain urticaria, which
denotes a non-vasculitic itchy oedema of multiple or
idiopathic origin (fig 1C), prurigo simplex, showing itchy
papular lesions of a generally benign nature that may be
associated with liver disease, diabetes and paraneoplasia
(fig 1D),27 or from erythema multiforme (not shown). Figure 2
depicts findings from a patient with cryoglobulinaemic
vasculitis. Early necrotic lesions at the medial foot sole can be
seen (fig 2A, C) which developed into late necrosis after several
weeks of corticosteroid treatment (fig 2D). In addition, small
macular necrotic lesions can be seen (fig 2B). Necrosis of the
toes has also been described with cryoglobulinaemic vasculitis
(not shown).
To secure the diagnosis, a skin biopsy is always required to
define the histopathology, to search for deposition of immune
complexes and complement, and for the exclusion of non-
vasculitic cutaneous conditions such as pigmented purpuric
eruptions, scurvy, atheroembolic or thrombotic disease that
may clinically mimic vasculitis.6 28Figure 2E and 2F show the
histopathological pattern of leucocytoclastic vasculitis in the
patient with cryoglobulinaemic vasculitis. Leucocytoclasis
A B
C D
E F
Figure 2 Dermal findings in a patient with
type II cryoglobulinaemia associated with
chronic alcoholic liver disease in the absence
of viral hepatitis. (A) Symmetrical purpuric
papular lesions on the medial aspect of the
foot soles and (B) petechial macular lesions
on the dorsal aspect of the foot on
presentation. (C) Magnification of the boxed
area from (A). (D) Partial healing of the foot
sole lesion after 8 weeks of oral steroid
treatment. (E) Skin biopsy from the leg,
vertical section. Biopsy confirmed the
presence of vasculitis by showing infiltration
of the perivasculature with leucocytes and
cell dust (so-called leucocytoclastic
histopathological pattern). From top to
bottom: stratum corneum, normal epidermis
circumscribing a hair follicle (indicated by
asterisk), dermis. Two vascular regions
exhibiting wall thickening and extravasation
of cells are highlighted by the box and
arrowheads, respectively (haematoxylin-
eosin stain, magnification 1006). (F)
Magnification of the boxed area from (E).
Note vascular wall thickening and
extravascular accumulation of leucocyte
nuclei and cell dust (haematoxylin-eosin
stain, magnification 3006). Presence of type
III cryoglobulin in the absence of other
pathological immune serologies or evidence
of neoplasm or internal organ involvement
confirmed the diagnosis of isolated dermal
cryoglobulinaemic vasculitis.
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denotes the presence of leucocytic vascular/perivascular infil-
trates and leucocytic cell dust.6 28 However, such a pattern in
haematoxylin-eosin stained specimens is seen in almost all
vasculitides, independent of aetiology.6 28 Only additional analysis
for subtypes of deposited immune complexes and possible
complement allow for further aetiological differentiation.
A complete vasculitis workup should also include fundo-
scopy29 and a comprehensive panel of immune serologies.
Investigations searching for infections and neoplasms may also
be necessary to establish the type and aetiology of the vasculitis,
as well as the degree of extradermal organ involvement.6 28
RENAL COMPLICATIONS
All three main types of cryoglobulinaemic vasculitis can lead to
kidney disease, as summarized in table 6. In brief, membrano-
proliferative glomerulonephritis (MPGN) type I is typical. Up to
10–30% of patients with chronic HCV infection develop MPGN
I. Very recently, 146 patients with cryoglobulinaemic vasculitis-
associated renal disease from Italy were studied. The mean-age
was 52 years, 87% of patients were found to be infected with
HCV (98% genotypes 1b and 2), ,85% had MPGN I and ,7%
had mesangioproliferative glomerulonephritis on renal biopsy.53
Generally, cryoglobulin associated MPGN I can present with
either proteinuria (41%), the nephritic syndrome (21%), the
nephritic syndrome (14%; marked by urinary erythrocyte
acanthosis, fig 3), and both chronic (12%) and acute (9%)
renal failure.12 33 36 53 Extrarenal symptoms such as skin
involvement may be absent in 30–80% of cases.37 53 On histology
MPGN I exhibits subendothelial deposition of cryoglobulin
immune complexes and often complement c3 in the glomerular
basement membrane. Because of subsequent mesangial cell
proliferation, there is marked thickening of the glomerular
basement membrane and glomerular hypercellularity (fig 4).
TREATMENT OF CRYOGLOBULINAEMIC VASCULITIS
Asymptomatic cryoglobulinaemia merits no treatment. Therapy
of secondary cryoglobulinaemic vasculitis is aimed at the
primary disease, as summarised in table 7. For HCV associated
cryoglobulinaemic vasculitis type II, antiviral strategies aiming
at cure of HCV infection, as outlined in table 7, have been
shown to be clearly superior to conventional immunosuppres-
sion.46 However, some controversy remains concerning the
effectiveness of anti-HCV treatment in patients with active
cryoglobulinaemic vasculitis.47 Recently, an entirely new
approach of treating cryoglobulinaemic vasculitis by direct
blockage of complement C5 has been suggested and has been
demonstrated to be effective in a mouse model.48 This finding is
of potential interest for future treatment strategies in humans.
PROGNOSIS
The prognosis of mixed cryoglobulinaemic vasculitis is benign
in 50% of cases. However, one third of cases are reported to
have a moderate to severe course, particularly because of renal
and/or hepatic insufficiency. Consequently, 10 year survival
rates are significantly lower than in the normal population.20
According to recent data from small patient numbers, antiviral
treatment may cure or control HCV associated mixed cryoglo-
bulinaemic vasculitis and possibly improve prognosis.38 In
previous studies, the survival of MPGN I patients not stratified
for aetiology was significantly lower than in the normal
population: 50% of patients progressed to end stage renal
disease (ESRD) within 10 years and the recurrence rate in
patients with renal transplants was 30–70%. A number of
recent small studies have reported successful MPGN I treat-
ment using antiviral strategies (see table 7). Further large
studies and follow-up data are needed to determine the benefit
of HCV treatment on the course of both cryoglobulinaemic
vasculitis and MPGN I. The topic is of importance as MPGN I is
a major cause of glomerulonephritis all over the world.49 The
prognosis of cryoglobulinaemia with no identified underlying
disease (essential mixed cryoglobulinaemia) is not well known,
and renal involvement is associated with a poor prognosis
(renal failure in 10% of patients).50 However, recently a
potentially promising therapeutic approach using the CD-20
antibody rituximab has been suggested.38
Figure 3 Urinary acanthocyte, a dysmorphic erythrocyte with abnormal
membrane blebs, indicating glomerular haematuria.
Table 6 Association of cryoglobulinaemic vasculitis with kidney disease
Cryoglobulinaemia Frequency
Associated kidney
disease Pathogenesis Reference
Type I Usually not Glomerulonephritis Hent30
Rare Tubular damage (Fanconi
syndrome), depositions in
the GBM and mesangium
Plasma cell dyscrasia-
associated light chain
and amyloid depositions
Kumar31
Type II Most
common
(,75%)
Glomerulonephritis: MPGN I*
(,85%)
Mesangioproliferative GN
(,7%)
Fibronectin specific
monoclonal IgM leading
to glomerular leucocyte
attraction and damage
Johnson,12 33
Fornasieri32
Roccatello53
Type III Much less
common
(,25%)
Glomerulonephritis: MPGN I*
(,85%)
Mesangioproliferative GN
(,7%)
Unknown, possibly like
cryoglobulinaemia type II
Johnson,12 33 Fabrizi,34
Beddhu 35
Roccatello53
GN, glomerulonephritis; GBM, glomerular basement membrane; MPGN, membranoproliferative glomerulonephritis.
*Almost invariably associated with hepatitis C virus (HCV) infection. Cryoglobulins in the absence of HCV infection are
only rarely associated with MPGN I.34 36
Cryoglobulinaemic vasculitis 91
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CONCLUSIONS AND PERSPECTIVE
In recent years, considerable progress has been made in the
availability of routine diagnosis and epidemiological study of
hepatitis C infection, clearly demonstrating its association with
cryoglobulinaemia of types II and III. The concept that chronic
HCV infection underlies the majority of cases of cryoglobuli-
naemia is now widely acknowledged. On average, HCV infected
patients develop cryoglobulinaemia in 30–50% of cases and
MPGN type I in 10–30% of cases. Up to 2–15% of patients with
cryoglobulinaemia develop overt cryoglobulinaemic vasculitis.
Treatment should be directed towards aetiology rather than
symptomatic. HCV infection, as the most common possible
underlying condition, has to be excluded in every case.
Experience with and data on antiviral treatment options have
grown considerably in recent years. A 48 week course of
combined peginterferon and ribavirin represents the current
gold standard of anti-HCV therapy.
ACKNOWLEDGEMENTS
The authors are indebted to Drs E Gro¨ne and H-J Gro¨ne from the
Department of Cellular and Molecular Pathology, German Cancer
Research Centre, Heidelberg, Germany, for kindly providing electron
microscopic images.
A B
D E
B
D C
C
USP
MES
GBM
CL
P
US
P
10 µm
1µm 1µm
P
*
*
Figure 4 Renal biopsy samples of membranoproliferative glomerulonephritis (MPGN) type I. CL, capillary lumen; US, urinary space; MES, cell proliferation
in mesangium; P, podocytes; GBM, glomerular basement membrane. (A) Electron microscopy showing subendothelial and mesangial electron dense
immune deposits (N), an increase in cells in the mesangium and segmental duplication of the glomerular basement membrane (arrows). Foot processes of
podocytes are partially maintained (arrowheads) and partially not preserved (asterisk). Boxes indicate areas magnified in (B–D), respectively. (B) Doubling
of the GBM (arrow) and loss of podocyte foot processes (asterisk). (C) Preserved podocyte foot processes (arrowhead) and cross sections of large podocyte
processes (P). (D) Subendothelial electron dense immune deposits (N). (E) Light microscopy, periodic acid–Schiff staining (magnification 2006). The
glomerulus appears lobulated (arrows), hypercellular and with increased mesangial matrix. Individual capillary loops are occluded by homogenous
hyalinous material (arrowheads). Silver stains can also be performed, to discern the double contour of the thickened GBM on light microscopy, also referred
to as ‘‘tramtrack’’ sign (not shown). Immunofluorescence techniques provide molecular proof of immunoglobulin and possibly complement deposition within
the GBM (not shown).
Teaching points
(1) Cutaneous vasculitis is diagnosed by combining laboratory
analysis and histology, including staining for immunoglo-
bulin and complement deposits.
(2) Type I cryoglobulinaemia usually results from paraprotei-
naemic neoplasm eventually leading to myeloma kidney
and, very rarely, glomerulonephritis.
(3) Type II and III (‘‘mixed’’) cryoglobulinaemias result mostly
from hepatitis C virus (HCV) infection and in this
association can cause glomerulonephritis, especially mem-
branoproliferative glomerulonephritis (MPGN) I. Up to 10–
30% of patients with longstanding HCV infection develop
glomerulonephritis. 70–90% of MPGN I cases are asso-
ciated with HCV and type II cryoglobulins. Type II
cryoglobulinaemia is also associated with HIV infection,
liver disease and lymphoma. Type III cryoglobulinaemia
causes renal disease less often.
Recommended further reading
(i) on cryoglobulinaemic vasculitis38
(ii) on recent aspects and treatment of HCV infection38 39 51 54
(iii) on membranoproliferative glomerulonephritis52 53
(iv) on cutaneous vasculitis6
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HCV associated CV type I
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